Beijing Neox Biotech Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN)-targeting moiety covalently bound to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker reported to be useful for the treatment of cancer.